G Bradley Cole Sells 8,290 Shares of Genomic Health Inc. (GHDX) Stock
Genomic Health Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 8,290 shares of the stock in a transaction on Monday, October 10th. The stock was sold at an average price of $30.59, for a total value of $253,591.10. Following the sale, the chief operating officer now owns 39,426 shares of the company’s stock, valued at $1,206,041.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
G Bradley Cole also recently made the following trade(s):
- On Thursday, August 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $28.87, for a total value of $144,350.00.
Shares of Genomic Health Inc. (NASDAQ:GHDX) opened at 29.03 on Friday. The stock has a 50 day moving average price of $28.28 and a 200 day moving average price of $27.30. The firm’s market capitalization is $968.03 million. Genomic Health Inc. has a 12 month low of $20.05 and a 12 month high of $35.79.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The business had revenue of $81.97 million for the quarter, compared to analysts’ expectations of $81.27 million. Genomic Health had a negative net margin of 8.84% and a negative return on equity of 21.02%. The firm’s revenue was up 16.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) EPS. On average, analysts expect that Genomic Health Inc. will post ($0.47) earnings per share for the current year.
Several research firms have commented on GHDX. Canaccord Genuity reissued a “buy” rating and set a $38.00 target price on shares of Genomic Health in a research report on Friday, August 5th. Zacks Investment Research raised shares of Genomic Health from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Tuesday, October 4th. Bank of America Corp. set a $28.00 target price on shares of Genomic Health and gave the stock a “sell” rating in a research report on Wednesday, August 3rd. Jefferies Group increased their target price on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, August 17th. Finally, Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $32.50.
A number of large investors have recently bought and sold shares of the stock. Loomis Sayles & Co. L P bought a new stake in Genomic Health during the first quarter valued at approximately $15,639,000. Eagle Asset Management Inc. bought a new stake in Genomic Health during the third quarter valued at approximately $8,417,000. Ghost Tree Capital LLC bought a new stake in Genomic Health during the second quarter valued at approximately $5,179,000. Renaissance Technologies LLC boosted its stake in Genomic Health by 54.0% in the first quarter. Renaissance Technologies LLC now owns 446,021 shares of the company’s stock valued at $11,048,000 after buying an additional 156,421 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in Genomic Health during the second quarter valued at approximately $1,983,000. 88.92% of the stock is currently owned by institutional investors and hedge funds.
About Genomic Health
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.